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Accumulation of intramuscular long-chain acyl-CoA esters (LCACoA) has previously in animal and human models been suggested to play an
important role in lipid induced insulin resistance. The aim of this study was to examine whether myotubes established from type 2 diabetic (T2D)
subjects and lean controls express differences in long-chain acyl-CoA esters (LCACoA) precultured under physiological conditions and during
chronic exposure to palmitate (PA) and oleic acids (OA) with/without acute insulin stimulation. No significant differences were found between
diabetic and control myotubes, neither in the total amount nor among individual LCA–CoA species during basal and acute insulin stimulation.
LCA–CoA accumulated during exposure to palmitic acid but not during exposure to oleic acid. During PA and OA exposure, only palmitoyl-CoA,
oleoyl-CoA and total LCA–CoA change. PA exposure increased the palmitoyl-CoA, whereas oleoyl-CoAwas reduced and vice versa during OA
exposure. No differences were found in the LCA–CoA level between T2D and control subjects, neither in the total amount nor in the individual
specific LCA–CoA species during fatty acid exposure. Chronic (24 h), high PA, but not OA exposure induced insulin resistance at the level of
glycogen synthesis in control subjects. These results indicate that (1) no primary defects are responsible for LCA–CoA accumulation in diabetic
subjects; (2) LCA–CoA changes in vivo are partly adaptive to changes in the PA level and possibly other saturated fatty acids; and (3) PA induced
insulin resistance may be mediated through an increased level of palmitoyl-CoA.
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Type 2 diabetes (T2D) is characterized by hyperglycemia,
hyperinsulinemia, reduced ability to oxidize fat, and triacylgly-
cerol (TAG) accumulation in skeletal muscle fibres. Impaired
glucose transport and glycogen synthesis are well documented
in insulin resistant subjects [1–3], but lipid metabolism is less
clearly understood. A majority of in vivo studies investigating
the importance of free fatty acids (FFA) and TAG suggest
that increased plasma FFA and TAG concentrations are
associated with insulin resistance [4–12]. Increased plasmaAbbreviations: T2D; type 2 diabetes; LCACoA; long-chain acyl-CoA esters;
TAG; triacylglycerol; DAG; diacylglycerol; OA; oleic acid; PA; palmitic acid;
HI; high insulin concentration; BSA; bovine serum albumin; FCS; fetal calf
serum; GIR; glucose infusion rates; FFA; free fatty acid; HPLC; high pressure
liquid chromatography
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doi:10.1016/j.bbadis.2006.05.005FFA availability has been associated with insulin resistance in
several experiments, showing that insulin resistance can be
induced within hours by lipid infusion [11–14], or within weeks
by feeding rats a high-fat diet [15–17]. The responsible
mechanism for the induction of insulin resistance remains at
present unclear.
Focus has increasingly turned to the long chain acyl-CoA
esters (LCACoA) as a part of the development of insulin resist-
ance. Hulver et al. have demonstrated an increased muscular
LCA–CoA content in obese and extremely obese subjects com-
pared with normal weight subjects [18]. Rodents fed with a
high-fat diet showed an increased intramuscular LCA–CoA
content associated with insulin resistance [19]. LCA–CoA are
a substrate for the synthesis of triglycerides, phospholipids
and second messengers as diacylglycerol (DAG) and cera-
mides [20,21]. The latter have been associated with the
pathogenesis of insulin resistance [22–24]. These observations
have led to the hypothesis that LCA–CoA concentration is an
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Several studies have documented differences in the metabolism
of different fatty acids [19,21–24]. However, the impact of
various fatty acids on LCA–CoA has not been elucidated. Thus,
it is not yet clarified whether there are any differences between
control and diabetic subjects in the LCA–CoA level under
normophysiological conditions (genetic origin) or whether
these changes occur during exposure to various exogenous
lipids (adaptive). The intermediate metabolism of skeletal
muscle is highly influenced by physical activity, ageing,
substrate exposure, and fibre type composition rendering it
difficult to determine the contribution of genetic and environ-
mental factors to the LCA–CoA level in human skeletal muscle.
Cultured myotubes offer a unique model for separating the
genetic influence on insulin resistance and T2D from
environmental factors [24–29].
In order to determine to which extent abnormalities in LCA–
CoA levels are intrinsic or acquired in T2D, we determined the
total LCA–CoA content and the specific LCA–CoA fractions
by fluorescence dependent reverse phase high pressure liquid
chromatography (HPLC) before and after acute exposure to
high insulin concentration and/or PA or OA in myotubes
established from control subjects and T2D patients.
2. Methods
2.1. Human study subjects
Ten lean control subjects matched to ten obese T2D patients participated in
the study (Table 1). Muscle biopsies were obtained from the vastus lateralis
muscle by needle biopsy under local anaesthesia. Diabetic patients were treated
with either diet alone or in combination with sulfonylurea, metformin or insulin
withdrawn 1 week before the study. The patients suffered from no diabetic
complications except from simplex retinopathy. The control subjects had normal
glucose tolerance and no family history of diabetes. All subjects gave written
informed consent and the study was approved by the local ethics committee of
Funen and Vejle County.
2.2. Materials
Dulbecco's modified Eagle's medium, fetal calf serum (FCS), Ultroser G,
penicillin-streptomycin-amphotericin B and trypsin-EDTA were obtained from
Life Technology (Scotland, UK). Protein assay kit was purchased from BioRadTable 1
Clinical characteristics
Control T2D
N 10 10
Age (years) 51±1 50±1*
Weight (kg) 71.6±3.0 102.2±4.1
BMI (kg/m2) 24.2±0.5 33.5±1.1*
Fasting plasma glucose (mM) 5.7±0.1 10.0±0.7*
Fasting serum insulin (pM) 24.3±5.7 94.6±10.1*
Glucose infusion rate (mg/min) 383.3±20.4 117.8±18.6*
HbA1c (%) 5.5±0.1 7.7±0.5*
Fasting total cholesterol (mM) 5.29±0.22 5.42±0.37
Fasting LDL cholesterol (mM) 2.94±0.22 3.20±0.27
Fasting HDL cholesterol (mM) 1.85±0.15 1.36±0.03*
Fasting plasma triglyceride (mM) 1.12±0.16 1.93±0.40
Data are means±SE. *Significant different from controls (P<0.05).(Copenhagen, DK). PA, bovine serum albumin (BSA) (essentially fatty acid
free), L-carnitine and ECM-gel were purchased from Sigma Chemical Co. (St.
Louis, USA). Insulin Actrapid was from Novo Nordisk (Bagsvaerd, DK).
2.3. Cell culture
Cell cultures were established as previously described [30,31]. In brief,
muscle tissue was minced, washed and dissociated for 60 min by three
treatments with 0.05% trypsin-EDTA. The cells harvested were pooled and FCS
was added to stop trypsination. The cells obtained were seeded for up-scaling on
ECM-gel coated dishes after 30 min of preplating. Cell cultures were established
in DMEM medium supplemented with 10% FCS, 50 U/ml penicillin, 50 μg/ml
streptomycin and 1.25 μg/ml amphotericin B. After 24 h cell debris and non-
adherent cells were removed by changing the growth medium to DMEM
supplemented with 2% FCS, 2% Ultroser G, 50 U/ml penicillin, 50 μg/ml
streptomycin and 1.25 μg/ml amphotericin B. Cells were subcultured twice
before final seeding. At 75% confluence the growth medium was replaced by
basal medium (DMEM supplemented with 2% FCS, 50 U/ml penicillin, 50 μg/
ml streptomycin, 1.25 μg/ml amphotericin B and 25 pmol/l insulin) in order to
induce differentiation. The cells were cultured in humidified 5% CO2
atmosphere at 37 °C and medium was changed every 2–3 days.
2.4. Experimental design
Human myotubes established from controls and T2D subjects were allowed
to differentiate for 8 days under physiological conditions, i.e., 0.24 mmol/l fatty
acid free BSA, 0.5 mmol/l L-carnitine, 20 mmol/l HEPES, 25 pmol/l insulin, and
5.5 mmol/l glucose. All myotube cultures were used for analysis day 8 after
onset of differentiation. The last 24 h, myotubes were exposed to the following
protocol: Sister cultures were exposed to either (1) baseline medium, (DMEM
medium supplemented with 0.24 mmol/l fat-free albumin, 50 U/ml penicillin,
50 μg/ml streptomycin, 1.25 μg/ml amphotericin B, and 25 pmol/l insulin); (2)
baseline medium supplemented with 1.0 μM insulin the last 4 h (acute insulin
stimulation); (3) baseline medium supplemented with 0.6 mM PA; (4) baseline
medium supplemented with 0.6 mM PA and subsequently supplemented with
1.0 μM insulin the last 4 h; (5) baseline medium supplemented with 0.6 mMOA;
or (6) baseline medium supplemented with 0.6 mM OA and subsequently
supplemented with 1.0 μM insulin the last 4 h. Myotubes were rinsed twice and
LCA–CoA were extracted and determined as described in Analysis. Under the
same conditions were the corresponding glycogen synthesis at basal and during
acute insulin stimulation determined. Furthermore, the glycogen synthesis were
measured in control myotubes exposed for a mixture of 0.3 mmol/l PA and
0.3 mmol/l OA (final conc. 0.6 mmol/l fatty acid) in order to clarify whether
oleate could neutralize the insulin resistance inducing effect of palmitate.
2.5. Analysis
Myotubes were established in a 100 mm Petri dish and incubated as earlier
indicated. Subsequently, cells were washed with PBS and scraped off with a
rubber policeman in 0.6 M perchloric acid. Cells were harvested by
centrifugation and washed twice with 10 mM perchloric acid and stored at
−80 °C until LCA–CoA extraction. Heptadecanoyl-CoA (33 pmol) and H2O
were added to a final volume of 800 μl prior to addition of 3 ml chloroform/
methanol (2:1). Cells were then homogenized with an Ultraturrax homogenizer.
Chloroform (1 ml) and H2O (1 ml) were added and vortexed vigorously. After
centrifugation (3000 rpm/10 min/4 °C), the interphase was recovered and dried
under a stream of N2. The LCA–CoAwere further extracted and derivatised to
fluorescent acyl etheno CoA esters using 0.5 M chloroacetoaldehyde, 0.5%
SDS, 0.15 M citrate, pH 4 (200 μl) essentially as described by Larson and
Graham [32].
Acyl-CoA derivatives were separated and analyzed by reverse phase HPLC
(Dionex) equipped with a 5 μm LUNA C18 column (250×2 mm) and a C18
guard column (4×2 mm) (both from Phenomenex) maintained at 40 °C. The
LCA–CoA were eluted with a constant flow of 0.4 ml/min. using solvent A
(80% acetonitrile, 20% 20 mM ammoniumacetate) and solvent B (95% 20 mM
ammoniumacetate, 5% acetonitrile) and the following gradient: 0–10 min., 20%
A 80% B to 25% A 75% B; 10–24 min., 25% A 75% B to 71% A 29% B; 24–
Fig. 1. LCA–CoA level in myotubes established from control and T2D patients
at basal and during acute insulin stimulation. Differentiated myotubes (day 8)
were established from controls and T2D patients. The level of LCA–CoA in
myotubes was determined at basal and after exposure for acute insulin
stimulation as described in “Research design and methods”. Data are means±
SEM. n=10.
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55 min., 71% A 29% B to 100% A 0% B; 55–56 min., 100% A 0% B to 20% A
80% B; followed by equilibration for 10 min. in 20% A 80% B. Peaks were
detected using a Dionex SF 2000 fluorescence detector. The excitation
wavelength was set to 230 nm and the emission wavelength to 420 nm. Peak
areas were integrated using Chromeleonc Version 6.50 (Dionex) and quantified
relatively to the internal heptadecanoyl-CoA standard. Identification of
individual LCA–CoA was performed using standard LCA–CoA mixtures
derivatised as above-mentioned. The detection level of our methods was
0.5 pmol AcylCoA/mg protein.
2.6. Glycogen synthesis (GS)
Cells were grown and differentiated in 12 well plates, as described above.
Cultures were exposed to DMEM supplemented with 0.24 mmol/l fat free
albumin, 50 U/ml penicillin, 50 μg/ml streptomycin, 1.25 μg/ml amphotericin B,
D-[14C(U)]glucose (1.0 μCi/well), and 25 pmol/l or 1 μmol/l insulin,
respectively, in order to study basal and insulin-stimulated GS. The reaction
was stopped after 4 h by aspirating the reaction mixture and rapidly rinsing each
well four times with PBS at 4 °C. Cells were solubilized by adding 0.5 ml 1.0 M
KOH and heated at 70 °C for 20 min. To the sample was added 100 μl saturated
Na2SO4, 100 μl 25 mg/ml glycogen in distilled water (freshly made) and 9 ml
ice-cold absolute ethanol and then left at −70 °C for 48 h for glycogen
precipitation. The tubes were centrifuged (2000×g, 20 min, 4 °C) and the
supernatant immediately removed and discarded. The glycogen precipitate was
redissolved in 500 μl distilled water by heating at 70 °C for 10 min, 9 ml ice-cold
absolute ethanol were added and then left at −20 °C for minimum 24 h. Again,
the tubes were centrifuged, the supernatants removed and 500 μl distilled water
was added and the glycogen dissolved. 500 μl was taken out for scintillation
counting [27].
2.7. Statistical analysis
All values are given as means±SEM for all experiments. For all statistical
evaluations the significance was established at the 0.05 level. Statistical
comparisons were performed with one way variance analysis (ANOVA) using
INSTAT 2.01 (GraphPad, San Diego, CA, USA).3. Results
3.1. Subject characteristics
Clinical characteristics of the lean and T2D patients are
shown in Table 1. Fasting plasma glucose, serum insulin, and
HbA1c levels were significantly higher in the diabetic group
compared with the lean controls. Fasting HDL cholesterol
concentrations were lower in T2D patient compared with lean
controls. During the steady state of the hyperinsulinemic
euglycemic clamp period, the glucose infusion rates (GIR)
were significantly lower in T2D patients compared with the lean
control subjects.
3.2. HPLC
The following LCA–CoA were detected and quantified:
C12, C14, C16, C18, C18:1, C18:2 and C20:4.
3.3. Baseline conditions
No significant differences were found between diabetic and
control myotubes, neither in the total amount (94.69±
9.02 pmol/mg versus 83.51±8.18 pmol/mg; P=0.64) noramong individual LCA–CoA species (Fig. 1). During basal
condition without exogenous fatty acids exposure the LCA–
CoA specie composition is C18:1 >C16>C20:4=C12=
C14=C18=C18:2 (Fig. 1).
3.4. Acute insulin-stimulation
Acute insulin stimulation did not significantly change LCA–
CoA levels compared to basal LCA–CoA levels in myotubes
established from control and T2D subjects neither between total
LCA–CoA nor in the single fractions (P>0.05) (Fig. 1).
No significant differences were found between diabetic and
control Myotubes.
3.5. PA and OA exposure
Cell cultures were exposed to 0.6 mM palmitic acid and
0.6 mM oleic acid respectively during 24 h in the presence or
absence of insulin (1 μM). The following individual LCA–CoA
species were identified: C12, C14, C16, C18, C18:1, C18:2
and C20:4. We showed no significant differences between
diabetic and control myotubes (P>0.05), neither in the total
amount nor in the individual LCA–CoA species during
exposure to fatty acids, wherefore data from the two groups
were pooled. During the exposure to fatty acids, no significant
(P>0.05) changes were found in the following LCA–CoA
fractions: C12, C14, C18, C18:2 and C20:4, whereas significant
changes were found in C16 (Fig. 2a), C18:1 (Fig. 2b) and in the
total amount (Fig. 2c).
3.6. C16-CoA
When supplementing the media with PA, the C16-CoA level
significantly increased (98.22±9.12 pmol/mg versus 16.11±
1.03 pmol/mg; P<0.0001) whereas when supplementing the
media with OA, C16-CoA significantly decreased compared
with baseline conditions (3.26±0.29 pmol/mg versus 16.11±
1.03 pmol/mg; P<0.001) (Fig. 2a). No further changes were
found during acute insulin stimulation.
Fig. 2. Levels of palmitoyl-CoA, oleoyl-CoA and total LCA–CoA in
myotubes exposed for palmitate and oleic acids. Differentiated myotubes
(day 8) were either cultured under physiological conditions (5.5 mmol/
l glucose, 25 pmol/l insulin), exposed to 0.6 mM palmitic acid (PA) or
0.6 mM oleic acid (OA) for 24 h and subsequently exposed to acute insulin
stimulation (1 μM) during the last 4 h as described in “Research design and
methods”. Levels of palmitoyl-CoA (C16-CoA) (a), oleoyl-CoA (C18:1-CoA)
(b) and total LCA–CoA (c) were determine at basal and after acute insulin
stimulation. Due to the lack of significant (P>0.05) differences between
myotubes established from control and T2D patients, the two groups are
pooled, n=20. Data are means±SEM. *P=0.05 versus basal. OP=0.05
versus PA.
Fig. 3. Impact of palmitate and oleic acids on the C18/18:1 ratio. In order to
evaluate the impact of PA and OA on stearoyl-CoA desaturase (SCA) the C18/
18:1 ratio was calculated. Data are means±SEM. *P=0.05 versus basal.
OP=0.05 versus PA. n=20. PA, palmitic acid; OA, oleic acid.
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When supplementing the media with PA, a significantly
C18:1-CoA decrease occurred compared with baseline condi-
tions (23.21±2.42 pmol/mg versus 46.38±3.52 pmol/mg;
P=0.00042), whereas a significant C18:1-CoA increase was
found when supplementing the media with OA (103.09±
6.53 pmol/mg versus 46.38±3.52 pmol/mg; P<0.0001) (Fig.
2b). No further changes were found during acute insulin
stimulation.3.8. Total CoA
The total LCA–CoA level was significantly increased during
PA exposure compared with baseline conditions (148.66±
14.03 pmol/mg versus 89.43±6.11 pmol/mg; P<0.05). OA
exposure did not significantly increase the total LCA–CoA
level (128.44±8.17 pmol/mg versus 89.43±6.11 pmol/mg;
P>0.05) (Fig. 2c). No further changes were found during acute
insulin stimulation exposure.
3.9. C18/C18:1 ratio
In order to evaluate the impact of PA and OA on stearoyl-
CoA desaturase (SCA), we determined the C18/18:1 ratio
(Fig. 3). No significant differences were found between diabetic
and control myotubes (data not shown). Insulin stimulation did
not change the ratio (data not shown). During PA exposure the
ratio increased significantly compared with baseline conditions
(0.36±0.03 versus 0.08±0.01, P<0.001), whereas during OA
exposure the ratio did not change significantly compared with
baseline conditions (0.03±0.00 versus 0.08±0.01, P>0.05).
3.10. Glycogen synthesis and exposure to OA or PA
Glycogen synthesis was studied to evaluate the impact of
OA, PA and OA/PA on the ability of insulin to stimulate glucose
metabolism. As previously shown, insulin mediated glycogen
synthesis was decreased on average by 30% in diabetic
myotubes and exposure to PA or OA did not change glycogen
synthesis (data not shown). In contrast preculturing control
myotubes with 0.6 mmol/l PA reduces significantly insulin
mediated increment of glycogen synthesis (P<0.001) while OA
or OA/PA exposure did not alter insulin mediated increment in
glycogen synthesis (P>0.67) (Fig. 4).
4. Discussion
In order to determine to which extent abnormalities in LCA–
CoA levels are intrinsic or acquired in T2D, we studied the
LCA–CoA levels and species in myotubes established from
lean and T2D subjects and how the LCA–CoALCA–CoA level
Fig. 4. Insulin-stimulated increment in glycogen synthesis (GS) in myotubes
established from control subjects and exposed to chronic high PA or OA
concentrations. Human satellite cell cultures were established from control
subjects, grown, and differentiated for 8 days under baseline conditions and
exposed to 0.6 mmol/l PA, 0.6 mmol/l OA, a mixture of 0.3 mmol/l PA and
0.3 mmol/l OAwith a final concentration of fatty acids of 0.6 mmol/l or without
fatty acids for 24 h. Basal and insulin stimulated GS were determined as
described inMethods. The impact of OA and PA on insulin stimulated increment
of GS was calculated as insulin stimulated GS minus basal GS in cultures
precultured under baseline conditions (baseline) or exposed for palmitate (PA) or
oleate (OA) or a (1:1) mixture of PA and OA (PA/OA). Data are shown as
mean±SEM. N= 10. aP<0.001 vs. baseline, bP≤0.05 vs. PA.
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ity. Traditionally, chromatographic methods [19,33] or mass
spectrometry (MS–MS) [18] are used to determine LCACoA.
Recently, a new technique has been described [32], based on the
conversion of LCA–CoA to fluorescent derivates, acyl etheno
CoA esters, allowing separating and analysis of different LCA–
CoA species by reverse phase HPLC and detection by a
sensitive fluorescence detector, which allow to detect, identify
and quantitative extremely low levels of LCACoA. The LCA–
CoA are the metabolic active form of fatty acids and are
metabolic substrates for oxidation, building blocks in complex
lipids and partitions readily into membranes thereby influencing
the membrane fluidity. LCA–CoA also regulate a large number
of cellular functions, such as enzymes involved in the
carbohydrate and lipid metabolism, translocases, ion channels,
proteases, protein kinases, gene expression, and protein
transport [20,34]. Thus, LCA–CoA could be a key player in
the development of insulin resistance. In accordance with this,
previous studies in animals and humans have shown an
increased LCA–CoA level in T2D compared with control
subjects [16,19,35,36]. In order to understand the mechanisms
underlying this difference, we studied the LCA–CoA level in
myotubes established from control and T2D subjects. Our study
shows that the genetic background was not responsible for
changes in the LCA–CoA and that an increase in intracellular
LCA–CoA is dependent on an increased availability of certain
fatty acids, i.e., palmitate and possibly other saturated fatty
acids. The primary source of circulating plasma lipids is
lipolysis in adipose tissue. The raised plasma fatty acid levels
seen in obese and subjects with T2D are based on lipolysis in
their increased mass of adipose tissue. Differences in intramyo-
cellular LCA–CoA level may also be affected by the rate of
lipid uptake, oxidative capacity and rate of incorporation ofacyl-CoA into triacylglycerol. Human myotubes have been
shown to express the fatty acid transporters CD36/FAT, FATP-1
and FABPpm [37]. Previously, we have shown that control
and diabetic myotubes have equal rates of PA and OA uptake
and accumulation of triacylglycerol despite that diabetic
myotubes expressed a reduced lipid oxidation [24,26,39].
Furthermore, acute insulin stimulation did not alter acyl-CoA
levels which is explained by that both lipid uptake and storage is
insulin sensitive and that lipid taken up based on insulin
stimulation is incorporated into triacylglycerol [26]. Taken
together, the increased LCA–CoA level described in skeletal
muscles in obese and diabetic patients is not an intrinsic defect
but rather based on extra muscular mechanism as increased
availability of fatty acids.
Recently we described that diabetic and control myotubes
utilize FFA to the same extent, but metabolize saturated and
unsaturated FA differentially. PA is accumulated in TAG and
DAG, while OA is not accumulated to the same extent [24]. In
the present study, PA but not OA, increases the total LCA–CoA
amount in human myotubes. Thus, the dietary fatty acid
composition affects the fatty acid profile of skeletal muscle
lipids, i.e., the LCACoA, in the membranes and in the TAGs.
Several in vivo studies have documented that unsaturated fatty
acids are preferable to saturated fatty acids, as the unsaturated
fatty acids do not induce the development of insulin resistance
[41–43]. Palmitate exposure induced insulin resistance at the
level of glycogen synthesis in lean myotubes which is in
accordance with previous observation of palmitates ability to
induce insulin resistance in lean but not in diabetic myotubes
[27,38,39]. It could be speculated whether primary and PA
induced insulin resistance may involve similar mechanisms.
However, at present the mechanism responsible for either
primary or PA induced insulin resistance is unknown. Further
studies are necessary to clarify this issue and whether palmitoyl
CoA by its self or though its derivates induces insulin resistance
as both ceramides [21,22,40] and DAG [23] has been associated
with the pathophysiology of insulin resistance.
A new finding in the present study is that PA reduce oleoyl-
CoA. The mechanism may be based on substrate inhibition on
stearoyl-CoA desaturase (SCD). SCD is the rate-limiting
enzyme catalysing the biosynthesis of monounsaturated fatty
acids from saturated fatty acids. The preferred substrates are
palmitoyl-CoA and stearoyl-CoA, which are converted into
palmitoleoyl-CoA and oleoyl-CoA, respectively [44,45]. Dur-
ing PA exposure, the palmitoyl-CoA may perform competitive
inhibition with stearoyl-CoA and the oleoyl-CoA may thereby
decrease. In line with this, we found an increased C18/C18:1
ratio during PA exposure. OA exposure reduced palmitoyl-CoA
and may be explained by product inhibition. OA could thereby
have a protective effect on insulin resistance induced by
palmitate. Myotubes exposed for a mixture of palmitate and
oleate did not express insulin resistance at the level of glycogen
synthesis indicating that unsaturated fatty acids may have a
protective effect in relation to saturated fatty acids. However,
further studies are necessary to strengthen this finding as (1) our
observation are based on a single concentration and it cannot be
excluded that a mixture with increased concentrations of both
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oleate and (2) could be combined with the measurement of
LCA–CoA to show the benefit of a mixture of saturated and
unsaturated fatty acids on the LCA–CoA profile in human
myotubes. Taken together, the present study shows that an
increased LCA–CoA level is adaptive to increased exposure to
saturated fatty acids like PA and may be important for induced
insulin resistance but cannot explain primary defects in diabetic
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